nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—ABCB1—Topotecan—cervical cancer	0.371	0.625	CbGbCtD
Pomalidomide—CYP3A4—Topotecan—cervical cancer	0.222	0.375	CbGbCtD
Pomalidomide—TNF—vagina—cervical cancer	0.0163	0.0972	CbGeAlD
Pomalidomide—Febrile neutropenia—Topotecan—cervical cancer	0.0126	0.0621	CcSEcCtD
Pomalidomide—Pelvic pain—Topotecan—cervical cancer	0.0125	0.0614	CcSEcCtD
Pomalidomide—CRBN—uterine cervix—cervical cancer	0.0115	0.0686	CbGeAlD
Pomalidomide—CRBN—decidua—cervical cancer	0.011	0.0653	CbGeAlD
Pomalidomide—CRBN—renal system—cervical cancer	0.0108	0.0641	CbGeAlD
Pomalidomide—Interstitial lung disease—Topotecan—cervical cancer	0.0107	0.0528	CcSEcCtD
Pomalidomide—TNF—lymph node—cervical cancer	0.0105	0.0629	CbGeAlD
Pomalidomide—CRBN—endometrium—cervical cancer	0.0104	0.062	CbGeAlD
Pomalidomide—CRBN—mammalian vulva—cervical cancer	0.0101	0.06	CbGeAlD
Pomalidomide—CRBN—uterus—cervical cancer	0.00959	0.0571	CbGeAlD
Pomalidomide—CRBN—female reproductive system—cervical cancer	0.00862	0.0514	CbGeAlD
Pomalidomide—Hyperbilirubinaemia—Topotecan—cervical cancer	0.00833	0.0411	CcSEcCtD
Pomalidomide—Bone pain—Topotecan—cervical cancer	0.00791	0.039	CcSEcCtD
Pomalidomide—CRBN—female gonad—cervical cancer	0.00784	0.0467	CbGeAlD
Pomalidomide—CRBN—vagina—cervical cancer	0.00779	0.0465	CbGeAlD
Pomalidomide—Pulmonary embolism—Topotecan—cervical cancer	0.00757	0.0374	CcSEcCtD
Pomalidomide—Neuropathy—Topotecan—cervical cancer	0.00711	0.0351	CcSEcCtD
Pomalidomide—Sepsis—Topotecan—cervical cancer	0.00657	0.0324	CcSEcCtD
Pomalidomide—CRBN—lymph node—cervical cancer	0.00504	0.03	CbGeAlD
Pomalidomide—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00485	0.0239	CcSEcCtD
Pomalidomide—Pancytopenia—Topotecan—cervical cancer	0.00451	0.0223	CcSEcCtD
Pomalidomide—Neutropenia—Topotecan—cervical cancer	0.00444	0.0219	CcSEcCtD
Pomalidomide—Weight increased—Topotecan—cervical cancer	0.00432	0.0213	CcSEcCtD
Pomalidomide—Pneumonia—Topotecan—cervical cancer	0.00426	0.021	CcSEcCtD
Pomalidomide—Infestation—Topotecan—cervical cancer	0.00424	0.0209	CcSEcCtD
Pomalidomide—Infestation NOS—Topotecan—cervical cancer	0.00424	0.0209	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Topotecan—cervical cancer	0.00415	0.0205	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Topotecan—cervical cancer	0.00401	0.0198	CcSEcCtD
Pomalidomide—Epistaxis—Topotecan—cervical cancer	0.004	0.0197	CcSEcCtD
Pomalidomide—CYP1A2—renal system—cervical cancer	0.00354	0.0211	CbGeAlD
Pomalidomide—Angiopathy—Topotecan—cervical cancer	0.00345	0.017	CcSEcCtD
Pomalidomide—Mediastinal disorder—Topotecan—cervical cancer	0.00343	0.0169	CcSEcCtD
Pomalidomide—Chills—Topotecan—cervical cancer	0.00341	0.0168	CcSEcCtD
Pomalidomide—Malnutrition—Topotecan—cervical cancer	0.00331	0.0163	CcSEcCtD
Pomalidomide—Back pain—Topotecan—cervical cancer	0.0032	0.0158	CcSEcCtD
Pomalidomide—Muscle spasms—Topotecan—cervical cancer	0.00318	0.0157	CcSEcCtD
Pomalidomide—PTGS2—epithelium—cervical cancer	0.00316	0.0188	CbGeAlD
Pomalidomide—PTGS2—uterine cervix—cervical cancer	0.00313	0.0187	CbGeAlD
Pomalidomide—Anaemia—Topotecan—cervical cancer	0.00306	0.0151	CcSEcCtD
Pomalidomide—Leukopenia—Topotecan—cervical cancer	0.00296	0.0146	CcSEcCtD
Pomalidomide—PTGS2—renal system—cervical cancer	0.00293	0.0175	CbGeAlD
Pomalidomide—Cough—Topotecan—cervical cancer	0.00289	0.0142	CcSEcCtD
Pomalidomide—PTGS2—endometrium—cervical cancer	0.00283	0.0169	CbGeAlD
Pomalidomide—Arthralgia—Topotecan—cervical cancer	0.00282	0.0139	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.0028	0.0138	CcSEcCtD
Pomalidomide—Infection—Topotecan—cervical cancer	0.00268	0.0132	CcSEcCtD
Pomalidomide—Nervous system disorder—Topotecan—cervical cancer	0.00265	0.0131	CcSEcCtD
Pomalidomide—Thrombocytopenia—Topotecan—cervical cancer	0.00265	0.013	CcSEcCtD
Pomalidomide—Skin disorder—Topotecan—cervical cancer	0.00262	0.0129	CcSEcCtD
Pomalidomide—Hyperhidrosis—Topotecan—cervical cancer	0.00261	0.0129	CcSEcCtD
Pomalidomide—PTGS2—uterus—cervical cancer	0.00261	0.0156	CbGeAlD
Pomalidomide—CYP3A4—renal system—cervical cancer	0.00256	0.0153	CbGeAlD
Pomalidomide—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00246	0.0121	CcSEcCtD
Pomalidomide—Dyspnoea—Topotecan—cervical cancer	0.00241	0.0119	CcSEcCtD
Pomalidomide—Decreased appetite—Topotecan—cervical cancer	0.00235	0.0116	CcSEcCtD
Pomalidomide—PTGS2—female reproductive system—cervical cancer	0.00235	0.014	CbGeAlD
Pomalidomide—Gastrointestinal disorder—Topotecan—cervical cancer	0.00233	0.0115	CcSEcCtD
Pomalidomide—Fatigue—Topotecan—cervical cancer	0.00233	0.0115	CcSEcCtD
Pomalidomide—Pain—Topotecan—cervical cancer	0.00231	0.0114	CcSEcCtD
Pomalidomide—Constipation—Topotecan—cervical cancer	0.00231	0.0114	CcSEcCtD
Pomalidomide—Feeling abnormal—Topotecan—cervical cancer	0.00223	0.011	CcSEcCtD
Pomalidomide—Body temperature increased—Topotecan—cervical cancer	0.00214	0.0105	CcSEcCtD
Pomalidomide—PTGS2—female gonad—cervical cancer	0.00214	0.0127	CbGeAlD
Pomalidomide—PTGS2—vagina—cervical cancer	0.00212	0.0126	CbGeAlD
Pomalidomide—CYP3A4—female reproductive system—cervical cancer	0.00205	0.0122	CbGeAlD
Pomalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—RARB—cervical cancer	0.00204	0.0559	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Topotecan—cervical cancer	0.00199	0.00982	CcSEcCtD
Pomalidomide—ABCB1—epithelium—cervical cancer	0.00195	0.0116	CbGeAlD
Pomalidomide—Asthenia—Topotecan—cervical cancer	0.00194	0.00956	CcSEcCtD
Pomalidomide—ABCB1—uterine cervix—cervical cancer	0.00194	0.0115	CbGeAlD
Pomalidomide—Pruritus—Topotecan—cervical cancer	0.00191	0.00943	CcSEcCtD
Pomalidomide—Diarrhoea—Topotecan—cervical cancer	0.00185	0.00912	CcSEcCtD
Pomalidomide—ABCB1—decidua—cervical cancer	0.00185	0.011	CbGeAlD
Pomalidomide—ABCB1—renal system—cervical cancer	0.00181	0.0108	CbGeAlD
Pomalidomide—Dizziness—Topotecan—cervical cancer	0.00179	0.00881	CcSEcCtD
Pomalidomide—ABCB1—endometrium—cervical cancer	0.00175	0.0104	CbGeAlD
Pomalidomide—Vomiting—Topotecan—cervical cancer	0.00172	0.00847	CcSEcCtD
Pomalidomide—Rash—Topotecan—cervical cancer	0.0017	0.0084	CcSEcCtD
Pomalidomide—Dermatitis—Topotecan—cervical cancer	0.0017	0.00839	CcSEcCtD
Pomalidomide—ABCB1—mammalian vulva—cervical cancer	0.00169	0.0101	CbGeAlD
Pomalidomide—Headache—Topotecan—cervical cancer	0.00169	0.00835	CcSEcCtD
Pomalidomide—ABCB1—uterus—cervical cancer	0.00161	0.00962	CbGeAlD
Pomalidomide—Nausea—Topotecan—cervical cancer	0.00161	0.00792	CcSEcCtD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—YY1—cervical cancer	0.00148	0.0404	CbGpPWpGaD
Pomalidomide—ABCB1—female reproductive system—cervical cancer	0.00145	0.00865	CbGeAlD
Pomalidomide—PTGS2—lymph node—cervical cancer	0.00137	0.00818	CbGeAlD
Pomalidomide—ABCB1—female gonad—cervical cancer	0.00132	0.00787	CbGeAlD
Pomalidomide—ABCB1—vagina—cervical cancer	0.00131	0.00782	CbGeAlD
Pomalidomide—TNF—Death Receptor Signalling—CASP8—cervical cancer	0.00125	0.0343	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—PIAS3—cervical cancer	0.000941	0.0258	CbGpPWpGaD
Pomalidomide—ABCB1—lymph node—cervical cancer	0.000849	0.00506	CbGeAlD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—WNT5A—cervical cancer	0.000754	0.0207	CbGpPWpGaD
Pomalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000722	0.0198	CbGpPWpGaD
Pomalidomide—TNF—Type II diabetes mellitus—MTOR—cervical cancer	0.000717	0.0196	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—HES1—cervical cancer	0.000703	0.0192	CbGpPWpGaD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—CASP8—cervical cancer	0.00063	0.0173	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-DPB1—cervical cancer	0.000615	0.0168	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—CD4—cervical cancer	0.000608	0.0166	CbGpPWpGaD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000577	0.0158	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—INSM1—cervical cancer	0.000572	0.0157	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—MTHFR—cervical cancer	0.000569	0.0156	CbGpPWpGaD
Pomalidomide—CYP1A2—Tryptophan metabolism—UBE3A—cervical cancer	0.000555	0.0152	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—CASP8—cervical cancer	0.00052	0.0142	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—CASP8—cervical cancer	0.00052	0.0142	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—CD8A—cervical cancer	0.000518	0.0142	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.0005	0.0137	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—STAT3—cervical cancer	0.000485	0.0133	CbGpPWpGaD
Pomalidomide—TNF—TNF receptor signaling pathway —CASP8—cervical cancer	0.000483	0.0132	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—HLA-DQB1—cervical cancer	0.00048	0.0131	CbGpPWpGaD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—CASP3—cervical cancer	0.000477	0.0131	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—CD4—cervical cancer	0.000472	0.0129	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—CASP8—cervical cancer	0.000467	0.0128	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—MTHFR—cervical cancer	0.000463	0.0127	CbGpPWpGaD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000445	0.0122	CbGpPWpGaD
Pomalidomide—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000429	0.0117	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—CASP3—cervical cancer	0.000426	0.0117	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000414	0.0113	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—CASP8—cervical cancer	0.000407	0.0111	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—CASP3—cervical cancer	0.000393	0.0108	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—CASP3—cervical cancer	0.000393	0.0108	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—CTNNB1—cervical cancer	0.000379	0.0104	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—MTHFR—cervical cancer	0.000367	0.0101	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—STAT3—cervical cancer	0.000366	0.01	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—MTOR—cervical cancer	0.000345	0.00944	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—cervical cancer	0.000342	0.00937	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CASP8—cervical cancer	0.000313	0.00858	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—CASP8—cervical cancer	0.000313	0.00858	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—CTNNB1—cervical cancer	0.00031	0.00849	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—CASP3—cervical cancer	0.000308	0.00843	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP8—cervical cancer	0.000298	0.00817	CbGpPWpGaD
Pomalidomide—CYP1A2—Estrogen Receptor Pathway—STAT3—cervical cancer	0.000295	0.00809	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	0.000279	0.00765	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	0.000279	0.00765	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—CASP8—cervical cancer	0.000278	0.0076	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—cervical cancer	0.000273	0.00748	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—STAT3—cervical cancer	0.00027	0.0074	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DPB1—cervical cancer	0.00027	0.00738	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—HES1—cervical cancer	0.000268	0.00735	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—HES1—cervical cancer	0.000265	0.00724	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000256	0.00702	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CASP8—cervical cancer	0.000256	0.007	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—cervical cancer	0.000246	0.00673	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—MTOR—cervical cancer	0.000246	0.00672	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CASP3—cervical cancer	0.000237	0.0065	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—CASP3—cervical cancer	0.000237	0.0065	CbGpPWpGaD
Pomalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cervical cancer	0.000229	0.00628	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—cervical cancer	0.000227	0.00622	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP3—cervical cancer	0.000226	0.00618	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—STAT3—cervical cancer	0.00022	0.00601	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—cervical cancer	0.000218	0.00596	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—cervical cancer	0.000212	0.00579	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—HLA-DQB1—cervical cancer	0.00021	0.00576	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—CASP3—cervical cancer	0.00021	0.00575	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000202	0.00554	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CASP8—cervical cancer	0.000199	0.00546	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—STAT3—cervical cancer	0.00019	0.0052	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP8—cervical cancer	0.000183	0.00501	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000182	0.00497	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—cervical cancer	0.00018	0.00494	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—cervical cancer	0.000176	0.00481	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	0.000173	0.00473	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CASP3—cervical cancer	0.000172	0.00471	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—CASP8—cervical cancer	0.000171	0.00469	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000155	0.00424	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—CTNNB1—cervical cancer	0.000154	0.0042	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—TP53—cervical cancer	0.000152	0.00417	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD4—cervical cancer	0.000152	0.00415	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—cervical cancer	0.000145	0.00397	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP3—cervical cancer	0.000138	0.00379	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CASP3—cervical cancer	0.000138	0.00377	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CASP8—cervical cancer	0.000137	0.00376	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—STAT3—cervical cancer	0.000134	0.00366	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CTNNB1—cervical cancer	0.000133	0.00365	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	0.000133	0.00363	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—EGFR—cervical cancer	0.000131	0.0036	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—CASP3—cervical cancer	0.00013	0.00355	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000117	0.00321	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000113	0.00309	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—cervical cancer	0.00011	0.00302	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CASP3—cervical cancer	0.000106	0.00291	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HES1—cervical cancer	0.000105	0.00288	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CASP3—cervical cancer	0.000104	0.00285	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—cervical cancer	9.91e-05	0.00271	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	9.77e-05	0.00268	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	9.77e-05	0.00268	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	9.57e-05	0.00262	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	8.94e-05	0.00245	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—cervical cancer	8.87e-05	0.00243	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—cervical cancer	8.32e-05	0.00228	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—cervical cancer	8.13e-05	0.00223	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NOTCH1—cervical cancer	7.94e-05	0.00217	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	7.51e-05	0.00206	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	7.24e-05	0.00198	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—WNT2—cervical cancer	7.08e-05	0.00194	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	6.98e-05	0.00191	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—cervical cancer	6.82e-05	0.00187	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	6.78e-05	0.00186	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CA9—cervical cancer	5.6e-05	0.00153	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	5.53e-05	0.00151	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—WNT5A—cervical cancer	5.37e-05	0.00147	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CTNNB1—cervical cancer	5.28e-05	0.00144	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	5.13e-05	0.00141	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	4.95e-05	0.00135	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	4.64e-05	0.00127	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—STAT3—cervical cancer	4.6e-05	0.00126	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—cervical cancer	4.18e-05	0.00114	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CA9—cervical cancer	3.97e-05	0.00109	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	3.92e-05	0.00107	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	3.29e-05	0.000901	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CA9—cervical cancer	3.17e-05	0.000868	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HES1—cervical cancer	3.09e-05	0.000846	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTHFR—cervical cancer	2.71e-05	0.000744	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TERT—cervical cancer	2.71e-05	0.000741	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGFR3—cervical cancer	2.48e-05	0.00068	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CA9—cervical cancer	2.45e-05	0.00067	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOTCH1—cervical cancer	2.33e-05	0.000639	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTHFR—cervical cancer	2.27e-05	0.000623	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTOR—cervical cancer	1.75e-05	0.000479	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—cervical cancer	1.74e-05	0.000478	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTHFR—cervical cancer	1.61e-05	0.000441	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CTNNB1—cervical cancer	1.55e-05	0.000424	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—cervical cancer	1.35e-05	0.00037	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTHFR—cervical cancer	1.29e-05	0.000352	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—cervical cancer	1.23e-05	0.000336	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTHFR—cervical cancer	9.93e-06	0.000272	CbGpPWpGaD
